PFAS Becomes the Next Asbestos
Enforceable drinking-water limits are forcing utilities and industrial users to spend on testing, filtration and remediation. Treatment vendors gain a long-duration installed base, while historical PFAS producers face settlements, legal costs and uncertain residual liabilities. The market is increasingly treating PFAS exposure as a balance-sheet issue rather than a routine environmental expense.
How this story could end...
The endings this story genuinely supports, written from the same evidence as the story updates. The value ranges are illustrative examples of how the affected companies as a group could re-rate — not forecasts, targets or advice.
Mapping out the endings…
How the two sides have traded
The bull and bear baskets for this story, equal-weighted and indexed so the two lines start together.
Each scenario's basket — 3 months
Both sides on one chart — 5 stocks on the bull side, 4 stocks on the bear side. The bull line is emphasised.
Each line tracks the 10 companies most exposed to this story, so a broad basket of loosely related names does not flatten it. The full list below is unchanged.
Jul 21, 2026 – Oct 19, 2026 · 60 sessions
Equal-weighted performance of the 10 most exposed stocks over the last 3 months.
Most affected stocks
Bull case
Veolia can monetize PFAS analysis, hazardous-waste handling and advanced municipal water treatment.
Stricter contamination standards support demand for residential, commercial and municipal filtration products.
Its high-purity and industrial water-treatment expertise is valuable as contaminant specifications tighten.
Its Evoqua platform supplies testing, treatment and remediation systems needed to remove PFAS from water.
Kurita benefits as Asian industrial customers adopt more sophisticated water purification and contaminant-control systems.
Reporting behind this story
Looking at what moved this story…